You just read:

Debiopharm and Aurigene Sign Agreement for the Development and Commercialisation of Debio 1142, a Novel Inhibitor of an Undisclosed Oncology Pathway

News provided by

Debiopharm Group

Apr 14, 2011, 03:00 ET